Published in J Virol on January 01, 1991
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 8.62
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol (1996) 5.59
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol (1991) 4.82
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (1992) 3.79
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol (1998) 3.60
Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol (1997) 3.46
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol (1994) 3.43
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol (1993) 3.32
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 3.13
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A (1991) 2.71
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol (1992) 2.51
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol (2001) 2.38
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol (1998) 2.03
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J Virol (2002) 1.99
Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci U S A (1991) 1.97
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol (1995) 1.80
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol (2003) 1.78
Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol (1997) 1.77
Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1996) 1.70
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol (1997) 1.66
A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.59
Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med (1996) 1.58
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol (1996) 1.57
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol (1995) 1.52
Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO J (1992) 1.47
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol (1996) 1.46
Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol (1996) 1.41
Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J Virol (1991) 1.40
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol (1994) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
Cellular and humoral antigenic epitopes in HIV and SIV. Immunology (1992) 1.38
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol (1999) 1.38
Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol (1992) 1.27
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol (2009) 1.26
Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. J Virol (1991) 1.26
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol (2010) 1.25
Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med (1991) 1.23
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol (1996) 1.22
A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol (1993) 1.16
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J Virol (1993) 1.16
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol (2006) 1.12
Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol (2005) 1.10
Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol (1993) 1.09
Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol (1996) 1.07
Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. J Virol (2001) 1.05
Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals. J Virol (1993) 1.05
Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest (1992) 1.05
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J Virol (1995) 1.03
A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. J Virol (1991) 1.03
Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J Virol (2012) 1.03
Estimating the stoichiometry of HIV neutralization. PLoS Comput Biol (2010) 0.99
Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol (1996) 0.98
Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest (1995) 0.96
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol (2003) 0.91
An algorithm for mapping positively selected members of quasispecies-type viruses. BMC Bioinformatics (2001) 0.90
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One (2010) 0.89
Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism. Proc Natl Acad Sci U S A (1993) 0.89
Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. J Virol (1997) 0.89
Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J Clin Invest (1992) 0.89
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science (1987) 13.52
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol (1985) 7.35
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science (1988) 3.08
Neutralizing monoclonal antibodies to the AIDS virus. AIDS (1988) 3.06
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res Hum Retroviruses (1990) 2.18
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (1989) 1.80
Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation. J Exp Med (1989) 1.59
The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4. Proc Natl Acad Sci U S A (1990) 1.55
Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120. J Immunol (1989) 1.36
Markers of HIV infection prior to IgG antibody seropositivity. JAMA (1989) 1.24
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med (1989) 10.74
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med (1997) 3.53
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 3.13
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol (2001) 2.79
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A (1991) 2.71
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med (1989) 2.45
Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome. Proc Natl Acad Sci U S A (1984) 2.32
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci U S A (1990) 2.29
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med (1997) 2.15
Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08
T-cell-rich B-cell lymphoma. A clinicopathologic study of eight cases. Am J Clin Pathol (1995) 2.02
Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 1.84
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (1989) 1.80
Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides (2006) 1.80
Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med (1993) 1.77
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol (2000) 1.76
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
Hepatitis associated with myocarditis. Unusual manifestation of infection with Coxsackie virus group B, type 3. N Engl J Med (1966) 1.68
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1. J Virol (1990) 1.64
Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl J Med (1980) 1.61
Improved tolerance of maize plants to salt stress by arbuscular mycorrhiza is related to higher accumulation of soluble sugars in roots. Mycorrhiza (2002) 1.60
Use of external shock-wave lithotripsy and adjuvant ursodiol for treatment of radiolucent gallstones. A national multicenter study. Dig Dis Sci (1989) 1.56
Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol (1979) 1.54
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology (2001) 1.52
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor. J Gen Virol (1987) 1.44
Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ (2005) 1.44
The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ (1998) 1.41
Field reversed configuration confinement enhancement through edge biasing and neutral beam injection. Phys Rev Lett (2012) 1.41
Enterobacter sakazakii meningitis in neonates. Pediatr Infect Dis J (1988) 1.39
Dynamic formation of a hot field reversed configuration with improved confinement by supersonic merging of two colliding high-β compact toroids. Phys Rev Lett (2010) 1.38
Infectious decay of human immunodeficiency virus type 1 in plasma. J Infect Dis (1993) 1.36
Quenching revisited: low level direct current inhibits amygdala-kindled seizures. Exp Neurol (1998) 1.36
Clinically silent primary adrenal lymphoma: a case report and review of the literature. Am J Hematol (1998) 1.36
Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol (1989) 1.34
Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med (1996) 1.34
CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro. J Virol (1990) 1.34
Human acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. J Biol Chem (1999) 1.33
Cytomegalovirus strain AD169 binds beta 2 microglobulin in vitro after release from cells. J Gen Virol (1987) 1.32
Identification of neurokinin B-expressing neurons as an highly estrogen-receptive, sexually dimorphic cell group in the ovine arcuate nucleus. Endocrinology (2000) 1.30
Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology (1996) 1.28
Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology (1991) 1.28
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol (1998) 1.28
Induction of auxotrophic mutations by treatment of Chinese hamster cells with 5-bromodeoxyuridine and black light. Proc Natl Acad Sci U S A (1972) 1.24
Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. Cancer Causes Control (1995) 1.22
Chromosome assignment of the human gene for galactose-1-phosphate uridyltransferase. Proc Natl Acad Sci U S A (1974) 1.20
Relationship between phenotypes of cell-function differentiation and pathobiological behavior of gastric carcinomas. World J Gastroenterol (2001) 1.17
Plasmacytic differentiation of circulating Epstein-Barr virus-infected B lymphocytes during acute infectious mononucleosis. J Exp Med (1981) 1.17
Cloning and sequence analysis of a new cellulase gene encoding CelK, a major cellulosome component of Clostridium thermocellum: evidence for gene duplication and recombination. J Bacteriol (1999) 1.17
Human immunodeficiency virus type 1 in a seronegative patient with visceral Kaposi's sarcoma and hypogammaglobulinemia. Am J Med (1989) 1.16
The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. J Gen Virol (1999) 1.15
The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol (2000) 1.13
Feruloyl esterase activity of the Clostridium thermocellum cellulosome can be attributed to previously unknown domains of XynY and XynZ. J Bacteriol (2000) 1.12
A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes Rev (2012) 1.12
The acquired immunodeficiency syndrome (AIDS) dementia complex. Ann Intern Med (1989) 1.10
Changes in breast sensitivity at puberty, during the menstrual cycle, and at parturition. Br Med J (1977) 1.08
Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology (1997) 1.08
Neuroendocrine basis of seasonal reproduction. Recent Prog Horm Res (1984) 1.08
Regio- and diastereoselective tandem rhodium-catalyzed allylic alkylation/Pauson-Khand annulation reactions. J Am Chem Soc (2001) 1.07
Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses (1993) 1.07
A physiologically compatible tissue-equivalent liquid bolus for microwave heating of tissues. Phys Med Biol (1979) 1.07
Good thermal dosimetry is essential to good hyperthermia research. Br J Radiol (1978) 1.07
Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation. Neuroreport (1995) 1.06
Cytomegalovirus in urine specimens has host beta 2 microglobulin bound to the viral envelope: a mechanism of evading the host immune response? J Gen Virol (1987) 1.06
Antigenic variation in gp120s from molecular clones of HIV-1 LAI. AIDS Res Hum Retroviruses (1993) 1.06
Observation of a charged charmoniumlike structure in e+ e- → π+ π- J/ψ at sqrt[s] = 4.26 GeV. Phys Rev Lett (2013) 1.05
Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol (2000) 1.05
Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. J Virol (1998) 1.04
Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Virol (1997) 1.04
IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun (1994) 1.04